MRNA Moderna

XNGS Up Position vs. buy zone Alert

Health Care

· How we analyze

About the company

Moderna is a US biotech company built on mRNA technology. It became known for its Covid-19 vaccine. It also develops vaccines against RSV and flu as well as cancer and other therapies based on mRNA. As of Oct 11, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Cambridge, USA

The company develops mRNA-based vaccines and therapies for infectious diseases, oncology and rare diseases. It markets the vaccines Spikevax and mNEXSPIKE against COVID and mRESVIA against the respiratory virus RSV. Revenue in 2025 came largely from the COVID vaccines. According to the company, mNEXSPIKE, launched in 2025, was ahead of its other products in the US retail channel as of the report. Its research comprises programs in infectious diseases, oncology and rare diseases, partly together with Merck.

Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +4.6%
  • 7 days −14.1%
  • 30 days +4.6%
  • 1 year +680.1%
Day range (last trading day)
−13.7%Price at 97% of the range+0.4%
52-week range
−89.3%Price at 80% of the range+22.4%
Distance from the all-time high
−58.2%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Where is the price relative to the buy zone?

In the buy zone

  1. Still far away
  2. Close
  3. In the buy zone
  4. Below

The price is in the pullback area after the last rise – the area our Elliott rule watches as the buy zone.

As of: Close of the 4-hour candle Oct 27, 2026, 18:30 · Buy zone in the trade plan · An observation, not investment advice

Rule (4-hour candles) Zone valid since Oct 22, 2026 · last changed on Oct 27, 2026

Watcher Full history: every change of the buy zone with its date.

Automated analysis (rule-based)

How we analyze

Timeframe 4 hours · As of Oct 27, 2026

Elliott wave analysis Moderna (4-hour candles): wave 2 retracing, buy zone 61.8–78.6% of the advance, invalid below the start of wave 1. Elliott count: Flat (type known only after C), Corrective pattern (downward), C in progress (2 of 3 guidelines) (smaller wave degree). Candlestick chart MRNA with 60 4-hour candles from Sep 16, 2026, 15:30 to Oct 27, 2026, 18:30. Price is in the buy zone. Rule setup: start on Oct 7, 2026, 15:30, high on Oct 21, 2026, 19:30, pullback low on Oct 27, 2026, 14:30. All values as the distance from the top of the buy zone. Buy zone (61.8 to 78.6%) 0 to −5.8% (targets and stop for this zone from Watcher), invalid on a close below the start (−13.1%). Elliott count: Flat (type known only after C), Corrective pattern (downward), C in progress (2 of 3 guidelines) (B = 137% of A; C = 225% of A), invalid on a close above +21.2%. smaller wave degree: Smaller wave degree: more sensitive turning-point detection, because no count fits at the usual degree – it describes shorter swings. Provisional – check the count yourself on the chart. No visible sub-waves in: A. Rule setup on 4-hour candles – the rule evaluates MRNA on this timeframe. Automated analysis (rule-based), not investment advice. MRNA · 4-hour candles · Automated analysis (rule-based) Price is in the buy zone Smaller wave degree: more sensitive turning points – check the count yourself on the chart Start High Pullback low 61.80% (0%) 78.60% (−5.8%) invalid (−13.1%) invalid on a close above +21.2% 0 A B C in progress (i) (ii) (iii) −30% −20% −10% 0% +10% +20% Sep 18 Sep 24 Sep 30 Oct 6 Oct 12 Oct 16 Oct 22 last candle Oct 27, 2026, 18:30 · not investment advice Axis and values in brackets: distance from the top of the buy zone in %
  • 4-hour candles (green = close above open, red = below)
  • Rule setup (blue line start → high → pullback low)
  • Buy zone (0.618–0.786) 0 to −5.8%
  • Setup void on a close below the start (level 1 = 100%)
  • Watcher Target 1, Target 2 and stop for this zone from Watcher
  • Elliott count (thin gold line, waves in circles; dashed circle = still in progress; small = subwaves; red dashed = invalidation level)
  • Dashed throughout with a label: fallback count (smaller wave degree) – provisional, check it yourself on the chart

Elliott count: Flat (type known only after C), Corrective pattern (downward), C in progress (2 of 3 guidelines) · B = 137% of A; C = 225% of A

smaller wave degree Smaller wave degree: more sensitive turning-point detection, because no count fits at the usual degree – it describes shorter swings. Provisional – check the count yourself on the chart.

Comparison: The rule treats the last rise as the possible start of an upward impulse (without checking its history and structure). The Elliott count reads it as countermove B in a correction.

Note: Flat type (regular, expanded, running) can only be decided once C is complete.

Note: Structure open: leg A cannot be broken down into sub-waves on this timeframe – provisional, check the count yourself on the chart.

Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.

How to draw it yourself
  1. Load the TradingView chart and choose the timeframe 4 hours (4-hour candles) – the buttons above the chart switch it as well.
  2. In the drawing toolbar on the left, choose the Fib Retracement tool (group with the horizontal lines).
  3. Click on the start of wave 1 (low of Oct 7, 2026 15:30) and drag to the high of Oct 21, 2026 19:30.
  4. The buy zone lies between the lines 0.618 and 0.786 (0 to −5.8%); line 1 is the start of wave 1 – if the price closes below it, the setup is void. The rule is only triggered by a candle close above the last swing high .
  5. Watcher Stop, Target 1 and Target 2 of this zone – and how to draw them – are available from Watcher.

On phones the drawing toolbar is hidden – drawing works better on a desktop.

Scenarios

Timeframe 4 hours · As of Oct 27, 2026 · from the Elliott count in the analysis chart

Weighting Main scenario (2 of 3 guidelines, medium) · no alternative

Weighting by guidelines met – not a probability.

smaller wave degree Smaller wave degree: more sensitive turning-point detection, because no count fits at the usual degree – it describes shorter swings. Provisional – check the count yourself on the chart. No visible sub-waves in: A.

Main scenario

medium · 2 of 3 guidelines

As long as the 4-hour close stays below the end of B, this applies: flat countermove downward in three waves (Flat, type known only after C), C in progress – count points to falling prices.

Invalid if the 4-hour close is above the end of B (+21.2% from the top of the zone)

Alternative

If that breaks, this count no longer applies. Currently no alternative that follows the rules.

The price pulled back into the buy zone (0 to −5.8% from its top) and last closed in the zone. Rule trigger: after the touch a swing high forms, and a daily close is above it. If the price closes below the start of wave 1 (−13.1%), the setup is void. All percentages: distance from the top of the buy zone.

In the TradingView chart: Draw the buy zone in the chart with the Fibonacci tool (instructions next to the wave chart) or as two horizontal lines (tool “Horizontal Line”). If the price closes below the start of wave 1 (−13.1%), the setup is void – without an entry of the rule.

Trade plan of the rule

Exit with a gain

Buy zone – Rule trigger: candle close above the swing high

  • Buy zone (Fibonacci 61.8–78.6%) Top = reference point of the percentages 0 to −5.8%

Exit at a loss

Watcher Target 1, Target 2 and stop for this zone – with distance in percent and reward/risk – are available from Watcher. Plans and pricing Percentages from the top of the buy zone (61.8%) – not a forecast.

Rule-based, long only, 4-hour candles. Not a forecast and not investment advice. Lesson: the buy zone in 4 minutes

Save zone

With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in · Sign up

Fundamental analysis

Moderna · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 20, 2026.

In short

  • Light green: Revenue grew over 5 years (+19.3% per year), at least as fast as the sector median.
  • Light red: Loss in the last fiscal year.
  • Light green: Debt not higher than usual in the sector.
  • Light red: Profit in 2 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 108.4M USD · Net income −216.2M USD · Net margin −199.5%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 205.8M USD · Net income −255.9M USD · Net margin −124.3%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 135.1M USD · Net income −384.7M USD · Net margin −284.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 60.2M USD · Net income −514.0M USD · Net margin −853.7%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 803.4M USD · Net income −747.1M USD · Net margin −93.0%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 18.5B USD · Net income 12.2B USD · Net margin 66.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 19.3B USD · Net income 8.4B USD · Net margin 43.4%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 6.8B USD · Net income −4.7B USD · Net margin −68.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 3.2B USD · Net income −3.6B USD · Net margin −110.0%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+19.3% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 19.3% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light red: Loss

−145.2% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue there was no profit but a loss of 145.16 USD. Five years ago the margin was −93.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.09 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 0.09 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 8 loss years

2 of 10 fiscal years with a profit

What does this mean? In 2 of the last 10 fiscal years the bottom line showed a profit. 8 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
1.9B USD
Revenue vs. prior year
−39.9%
Net income (FY)
−2.8B USD
Net income vs. prior year
–
EPS (FY)
-7.26 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
−2
Shares held vs. prior quarter
−100.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 20, 2026 · Balance sheet Jun 30, 2026 (filed Jul 31, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 1.9B−2.8B −145.2% −7.26 – –
2024Dec 31, 2024 3.2B−3.6B −110.0% −9.28 – –
2023Dec 31, 2023 6.8B−4.7B −68.8% −12.33 – –
2022Dec 31, 2022 19.3B8.4B 43.4% 20.12 – –
2021Dec 31, 2021 18.5B12.2B 66.1% 28.29 – –
2020Dec 31, 2020 803.4M−747.1M −93.0% −1.96 – –
2019Dec 31, 2019 60.2M−514.0M −853.7% −1.55 – –
2018Dec 31, 2018 135.1M−384.7M −284.8% – – –
2017Dec 31, 2017 205.8M−255.9M −124.3% – – –
2016Dec 31, 2016 108.4M−216.2M −199.5% – – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 145.0M−782.0M −539.3% −1.97 – –
Q1/26Mar 31, 2026 389.0M−1.3B −345.2% −3.40 – –
Q4/25*Dec 31, 2025 678.0M−826.0M −121.8% – – –
Q3/25Sep 30, 2025 1.0B−200.0M −19.7% −0.51 – –
Q2/25Jun 30, 2025 142.0M−825.0M −581.0% −2.13 – –
Q1/25Mar 31, 2025 108.0M−971.0M −899.1% −2.52 – –
Q4/24*Dec 31, 2024 966.0M−1.1B −115.9% – – –
Q3/24Sep 30, 2024 1.9B13.0M 0.7% 0.03 – –
Q2/24Jun 30, 2024 241.0M−1.3B −530.7% −3.33 – –
Q1/24Mar 31, 2024 167.0M−1.2B −703.6% −3.07 – –
Q4/23*Dec 31, 2023 2.8B217.0M 7.7% – – –
Q3/23Sep 30, 2023 1.8B−3.6B −198.3% −9.53 – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $62.6M4 people −$62.6M
6 months $00 people $72.4M6 people −$72.4M
12 months $00 people $81.6M6 people −$81.6M

Latest transactions

  • Oct 15, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 39,145 shares · $8.6M · SEC
  • Oct 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 450 shares · $96.4K · SEC
  • Oct 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 38,774 shares · $8.3M · SEC
  • Sep 15, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 40,281 shares · $5.9M · SEC
  • Sep 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 40,294 shares · $5.8M · SEC
  • Sep 10, 2026 Mock James M Chief financial officer (CFO) Open-market sale · 10b5-1 plan 15,000 shares · $2.0M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +90

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)46.5
Rel. strength 60 d+273.4%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MRNA yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MRNA

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

↑ ↓ select · Enter open · Esc close